Patent Assignment
Reel/Frame 061327/0712
Security Interest
Recorded: 2022-08-25
Pages: 39
Assignor
RIGEL PHARMACEUTICALS, INC.
Executed: 2022-07-27
Assignee
MIDCAP FINANCIAL TRUST
7255 WOODMONT AVE., SUITE 200, BETHESDA, MARYLAND, 20814
Covered Properties
(409)
2,4-Pyrimidinediamine Compounds and Their Uses
Application:
17/246,980 →
Publication:
US 2021/0267971
Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds
Application:
17/531,092 →
Publication:
US 2022/0073536
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Application:
16/806,541 →
Publication:
US 2020/0270271
Prodrug Salts of 2, 4-Pyrimidinediamine Compounds and Their Uses
Application:
17/581,586 →
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Axl Inhibitors for Use in Combination Therapy for Preventing, Treating or Managing Metastatic Cancer
Application:
17/351,996 →
Publication:
US 2021/0379064
Compositions and Methods for Inhibition of the Jak Pathway
Application:
16/733,571 →
Publication:
US 2020/0216431
Compositions and Methods for Inhibition of the Jak Pathway
Application:
17/494,370 →
Publication:
US 2022/0024907
Compounds and Method for Treating Autoimmune Diseases
Application:
17/547,819 →
Publication:
US 2022/0218705
Direct Ampk Activators
Application:
17/500,681 →
Publication:
US 2022/0098175
Fumarate Salt of 5-((5-Methyl-2-((3,4,5-Trimethylphenyl)Amino)Pyrimidin-4-Yl)Amino)-Benzo[D]Oxazol-2(3H)-One
Application:
17/057,983 →
Publication:
US 2021/0198248
Irak Inhibitors and Method for Making and Using
Pyrazole Compounds and Methods for Making and Using the Compounds
Application:
17/747,342 →
Publication:
US 2022/0289776
TGF-ß INHIBITORS
Application:
17/324,320 →
Publication:
US 2021/0276982
Benzazole Compounds and Methods for Making and Using the Compounds
Tyrosine Kinase Inhibitors
ACVR2A-Specific Antibody and Method of Use Thereof
Application:
17/394,228 →
Publication:
US 2021/0380703
2,4-Diamino-Pyrimidine Compounds and Method for Making and Using the Compounds
Amide Compounds and Method for Making and Using
Kinase Inhibitors and Methods for Making and Using
Application:
17/341,817 →
Publication:
US 2021/0309655
Antigen Binding Molecules to Tigit
Application:
16/925,818 →
Publication:
US 2020/0339678
Tyrosine Kinase Inhibitors
Application:
17/105,334 →
Publication:
US 2021/0078990
Method for Treating a Disease or Condition Using a Pyrazole Compound or Formulation Thereof
Pyrazole Compounds, Formulations Thereof, and a Method for Using the Compounds and/or Formulations
Application:
17/747,384 →
Publication:
US 2022/0306620
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
Method and Composition Embodiments for Treating Acute Myeloid Leukemia
Application:
17/290,741 →
Publication:
US 2022/0000880
Method of Preventing and Treating Thrombosis
Application:
16/888,430 →
Publication:
US 2020/0377518
Compounds and Method for Treating Cytokine Release Syndrome
Application:
17/592,779 →
Publication:
US 2022/0249475
Method of Blocking or Ameliorating Cytokine Release Syndrome
Application:
17/665,880 →
Publication:
US 2022/0152065
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
Application:
17/843,194 →
Publication:
US 2023/0112865
RIP1K Inhibitors
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
Application:
17/012,891 →
Publication:
US 2021/0070735
Heterocyclic RIP1 Kinase Inhibitors
Heterocyclic RIP1 Kinase Inhibitors
Method for Treatment of Covid-19-Associated Conditions
RIP1K Inhibitors
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
Heterocyclic RIP1 Inhibitory Compounds
Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated with Infection by a Respiratory Virus
Application:
63/241,973 →
Method for Treatment of an Excessive Immunological Response to an Infection by a Respiratory Virus
Application:
63/241,977 →
Crystalline Forms of a RIPK1 Inhibitor
Application:
63/290,066 →
Tricyclic Irak Inhibitors
Application:
63/325,957 →
Bicyclic Inhibitors of Irak
Application:
63/347,920 →
Pyrimid-2-Yl-Pyrazole Compounds as Irak Inhibitors
Application:
63/322,955 →
TGF-ß INHIBITORU
System and Method for High-Content Oncology Assay
Patent:
7,970,549 →
Application:
10/652,440 →
System and Method for High-Content Oncology Assay
Patent:
8,032,346 →
Application:
11/726,396 →
System and Method for High-Content Oncology Assay
System and Method for High-Content Oncology Assay
Substituted Diphenyl Heterocycles Useful for Treating Hcv Infection
Substituted Diphenyl Isoxazoles, Pyrazoles and Oxadiazoles Useful for Treating Hcv Infection
Substituted Diphenyl Heterocycles Useful for Treating Hcv Infection
2,4-Pyrimidinediamine Compounds and Their Uses
Intermediates Useful for Making 2,4-Pyrimidinediamine Compounds
5-Fluoro-4N-Phenyl-4-Pyrimidineamine Compounds
Methods of Treating or Preventing Autoimmune Diseases with 2, 4-Pyrimidinediamine Compounds
Methods of Treating or Preventing Autoimmune Diseases with 2, 4-Pyrimidinediamine Compounds
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds
Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds
2,4-Pyrimidinediamine Compounds for Treating or Preventing Autoimmune Diseases
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds for Treating or Preventing Autoimmune Diseases
Intermediates for Making 2,4-Pyrimidinediamine Compounds
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyridinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds
Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
2,4-Pyrimidinediamine Compounds and Their Uses
Inhibitors to Tubulin Polymerization
Methods and Compositions for Screening for Altered Cellular Phenotypes
Methods for Identifying Polypeptide Factors Interacting with Rna
Directionally Cloned Random Cdna Expression Vector Libraries, Compositions and Methods of Use
Modulators of Leukocyte Activation, Hck Compositions and Methods of Use
Methods of Identifying Compounds That Modulate Il-4 Receptor-Mediated Ige Synthesis Utilizing a CLLD8 Protein
Modulators of Leukocyte Activation, Bic Compositions and Methods of Use
Modulators of B-Lymphocyte Activation, Myosin-1F Compositions and Methods of Use
Pyridyl Substituted Heterocycles Useful for Treating or Preventing Hcv Infection
Pyridyl Substituted Heterocycles Useful for Treating or Preventing Hcv Infection
N2, N4-Bis-Aryi-5-Fluoro-2,4-Pyrimidinediamines
Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds
Patent:
7,812,029 →
Application:
12/028,581 →
Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds
Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds
2,4-Pyrimidinediamine Compounds and Uses as Anti-Proliferative Agents
2,4-Pyrimidinediamine Compounds and Uses as Anti-Proliferative Agents
2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents
Hcv Inhibitors and Methods of Using Them
Heterocyclic Compounds Having an Oxadiazole Moiety and Hydro Isomers Thereof
Diphenylisoxazole Compounds and Hydro Isomers Thereof
Methods and Compositions for the Identification of Anti-Poxvirus Agents
Rhodanine Compositions for Use as Antiviral Agents
Synergistically Effective Combinations of Dihaloacetamide Compounds and Interferon or Ribavirin Against Hcv Infections
2-Substituted Quinoline Compounds and Their Uses
Substituted Pyridines and Their Uses
Modulators of Angiogenesis
Methods for Cyclizing Synthetic Polymers
Methods for Cyclizing Synthetic Polymers
Heterotricyclic Compounds for Use as Hcv Inhibitors
4-Pyrimidineamine Compounds and Their Uses as Anti-Proliferative Agents
Stereoisomers and Stereoisomeric Mixtures of 1-(2,4-Pyrimidinediamino)-2-Cyclopentanecarboxamide Synthetic Intermediates
Cycloalkyl Substituted Pyrimidinediamine Compounds and Their Uses
Cycloalkyl Substituted Pyrimidinediamine Compounds and Their Uses
Cycloalkyl Substituted Pyrimidinediamine Compounds and Their Uses
Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses
Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses
Formulation of Insoluble Small Molecule Therapeutics in Lipid-Based Carriers
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4 Pyrimidinediamine Compounds and Their Uses
Patent:
7,563,892 →
Application:
11/539,074 →
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Spiro 2,4-Pyrimidinediamine Compounds and Their Uses
Spiro 2,4 Pyrimidinediamine Compounds and Their Uses
Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds and Their Uses
Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds and Their Uses
Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds and Their Uses
Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds and Their Uses
Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds and Their Uses
Stereoisomerically Enriched N-Protected Beta-Lactams Using Candida Antarctica
Benzisothiazoles Useful for Treating or Preventing Hcv Infection
Kinase Inhibitors and Their Uses
Kinase Inhibitors and Their Uses
Kinase Inhibitors and Their Uses
Kinase Inhibitors And Their Uses
Heterocyclic Anti-Viral Compounds Comprising Metabolizable Moieties and Their Uses
Pyrimidine-2,4-Diamines and Their Uses
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Methods of Treating Cell Proliferative Disorders
Methods of Treating Cell Proliferative Disorders
Methods and Compositions for Treating Degenerative Bone Disorders
Triazole Derivatives Useful as Axl Inhibitors
Triazole Derivatives Useful as Axl Inhibitors
Identification of Pharmacophores from Co-Crystals of Spleen Tyrosine Kinase (Syk) and Syk Ligands
Patent:
7,962,290 →
Application:
11/651,363 →
Pinane-Substituted Pyrimidinediamine Derivatives Useful as Axl Inhibitors
Pinane-Substituted Pyrimidinediamine Derivatives Useful as Axl Inhibitors
Cyclic Amine Substituted Pyrimidinediamines as Pkc Inhibitors
Protein Kinase C Inhibitors and Uses Thereof
Protein Kinase C Inhibitors and Uses Thereof
Protein Kinase C Inhibitors and Uses Thereof
Protein Kinase C Inhibitors and Uses Thereof
Diaminothiazoles Useful as Axl Inhibitors
Diaminothiazoles Useful as Axl Inhibitors
N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use
N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use
N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Bicyclic Aryl and Bicyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Bicyclic Aryl and Bicyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Bicyclic Aryl and Bicyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Bridged Bicyclic Aryl and Bridged Bicyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Bridged Bicyclic Aryl and Bridged Bicyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Bridged Bicyclic Aryl and Bridged Bicyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Polycyclic Aryl Substituted Triazoles and Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Polycyclic Aryl Substituted Triazoles and Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
N3-Heteroaryl Substituted Triazoles and N5-Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
N3-Heteroaryl Substituted Triazoles and N5-Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Substituted Triazoles Useful as Axl Inhibitors
Substituted Triazoles Useful as Axl Inhibitors
Substituted Triazoles Useful as Axl Inhibitors
Wet Granulation Using a Water Sequestering Agent
Wet Granulation Using a Water Sequestering Agent
Wet Granulation Using a Water Sequestering Agent
Ampk-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide and Amine Compounds and Methods for Using the Same
Ampk-Activating Piperidinyloxypyiridine Carboxamide and Sulfonamide Compounds and Methods for Using the Same
Ampk-Activating Piperidinyloxy-Substituted 2,3-Dihydro-1H-Indene-1-Amine Compounds and Pharmaceutical Compositions Including the Same
Carboxamide, Sulfonamide and Amine Compounds and Methods for Using the Same
Carboxamide, Sulfonamide and Amine Compounds and Methods for Using the Same
Carboxamide, Sulfonamide and Amine Compounds and Methods for Using the Same
Carboxamide Compounds and Methods for Using the Same
Carboxamide Compounds and Methods for Using the Same
Carboxamide Compounds and Methods for Using the Same
Carboxamide Compounds and Methods for Using the Same
Carboxamide Compounds and Methods for Using the Same
Carboxamide Compounds and Methods for Using the Same
Use of 2,4-Pyrimidinediamines For the Treatment of Atherosclerosis
Pyrimidine-2-Amine Compounds and Their Use as Inhibitors of Jak Kinases
Pyrimidine-2-Amine Compounds and Their Use as Inhibitors of Jak Kinases
Pyrimidine-2-Amine Compounds and Their Use as Inhibitors of Jak Kinases
Tricyclic Carbamate Jak Inhibitors
Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Bridged Bicyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Bridged Bicyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Bridged Bicyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Bridged Bicyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Synthesis of 2,4-Pyrimidinediamines
Synthesis of 2,4-Pyrimidinediamines
Synthesis of 2,4-Pyrimidinediamines
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Methods for Treating Inflammatory Disorders Using 2,4-Pyrimidinediamine Compounds
2,4-Pyrimidinediamine Compounds for Treatment of Inflammatory Disorders
Protein Kinase C Inhibitors and Uses Thereof
Protein Kinase C Inhibitors and Uses Thereof
Protein Kinase C Inhibitors and Uses Thereof
Axl Inhibitors for Use in Combination Therapy for Preventing, Treating or Managing Metastatic Cancer
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compounds and Method for Treating Autoimmune Diseases
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Patent:
47,396 →
Application:
14/918,353 →
Compounds and Method for Treating Autoimmune Diseases
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compounds and Method for Treating Autoimmune Diseases
Compositions and Methods for Inhibition of the Jak Pathway
Pyrimidinediamine Kinase Inhibitors
Pyrimidinediamine Kinase Inhibitors
Pyrimidinediamine Kinase Inhibitors
Small Molecule Inhibitors of Spleen Tyrosine Kinase (Syk)
Carboxamide Compounds and Methods for Using the Same
Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same
Carboxamide Compounds And Methods For Using The Same
Ampk-Activating Heterocyclic Compounds and Methods for Using the Same
Ampk-Activating Heterocyclic Compounds and Methods for Using the Same
Ampk-Activating Heterocyclic Compounds and Methods for Using the Same
Ampk-Activating Heterocyclic Compounds and Methods for Using the Same
Ampk-Activating Heterocyclic Compounds and Methods for Using the Same
Ampk-Activating Heterocyclic Compounds and Methods for Using the Same
Ampk-Activating Heterocyclic Compounds and Methods for Using the Same
2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses
2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses
2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses
Protein Kinase C Inhibitors and Uses Thereof
Screening Assay Employing Dex and GDF8
Mode of Action Screening Method
In Vivo Reporter System
Methods for Using Carboxamide, Sulfonamide and Amine Compounds
Methods for Using Carboxamide, Sulfonamide and Amine Compounds
Method for Making Macrocycles
Whole Blood Assay for Measuring Ampk Activation
Whole Blood Assay for Measuring AMPK Activation
Synthesis of Polycyclic Alkaloids
Synthesis of Polycyclic Alkaloids
Cyclopropyl Mida Boronate
Cyclopropyl Pida Boronate
Cyclopropyl MIDA Boronate
Treatment for Discoid Lupus
Treatment for Vitiligo
Treatment for Vitiligo
Methods for Inhibiting Allograft Rejection
Protein Kinase C Inhibitors and Uses Thereof
Protein Kinase C Inhibitors and Uses Thereof
Protein Kinase C Inhibitors and Uses Thereof
Protein Kinase C Inhibitors and Uses Thereof
Protein Kinase C Inhibitors and Uses Thereof
Protein Kinase C Inhibitors and Uses Thereof
Xinafoate Salt of N4-(2,2-Difluoro-4H-BENZ0 [1,4] Oxazin-3-One) -6-Yl] -5-Fluoro-N2- [3-(Methylaminocar Bonylmethyleneoxy) Phenyl] 2,4-Pyrimidinediamine
Xinafoate Salt of N4-(2,2-Difluoro-4H-Benzo[1,4]Oxazin-3-One)-6-Yl]-5-Fluoro-N2-[3-(Methylaminocarbonylmethyleneoxy)Phenyl]2,4-Pyrimidinediamine
GDF-8 Inhibitors
2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use
GDF-8 Inhibitors
GDF-8 Inhibitors
GDF-8 Inhibitors
2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use
(Trimethoxyphenylamino) Pyrimidinyl Formulations
(Trimethoxyphenylamino) Pyrimidinyl Formulations
Topical Formulation for Administering a Compound
Patent:
47,034 →
Application:
15/604,502 →
5- or 6-Substituted Benzofuran-2-Carboxamide Compounds and Methods for Using Them
Protein Kinase C Inhibitors and Uses Thereof
Protein Kinase C Inhibitors and Uses Thereof
Pharmaceutical Process and Intermediates
Pharmaceutical Process and Intermediates
Fumarate Analogs and Uses Thereof
Fumarate Analogs and Uses Thereof
Fumarate Analogs and Uses Thereof
Fumarate Analogs and Uses Thereof
Ubiquitination Inhibitors
Fused Imidazole Derivatives as TGF-Beta Inhibitors
Direct Ampk Activators
Tetrazolones as a Carboxylic Acid Bioisosteres
Tetrazolones as a Carboxylic Acid Bioisosteres
Tetrazolones as a Carboxylic Acid Bioisosteres
TGF-Beta Inhibitors
TGF-Beta Inhibitors
TGF-Beta Inhibitors
Pyrazole Compounds and Method for Making and Using the Compounds
Irak Inhibitors and Method for Making and Using
Pyrazole Compounds and Method for Making and Using the Compounds
Pyrazole Compounds and Method for Making and Using the Compounds
Pyrazole Compounds and Methods for Making and Using the Compounds
Irak Inhibitors and Method for Making and Using
TGF-ß InhibitorC
TGF-ß InhibitorO
Benzazole Compounds and Methods for Making and Using the Compounds
Benzazole Compounds and Methods for Making and Using the Compounds
Benzazole Compounds and Methods for Making and Using the Compounds
Nrf2 Activating Compounds and Uses Thereof
Nrf2 Activating Compounds and Uses Thereof
Nrf2 Activating Compounds and Uses Thereof
Nrf2 Activating Compounds and Uses Thereof
Nrf2 Activating Compounds and Uses Thereof
Nrf2 Activating Compounds and Uses Thereof
NRF2 Activating Compounds and Uses Thereof
Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors
ACVR2A-Specific Antibody and Method of Treatment of Muscle Atrophy
2,4-Diamino-Pyrimidine Compounds and Method for Making and Using the Compounds
Amide Compounds and Method for Making and Using
Amide Compounds and Method for Making and Using
Kinase Inhibitors and Methods for Making and Using
Kinase Inhibitors and Methods for Making and Using
Antigen Binding Molecules to Tigit
Tyrosine Kinase Inhibitors
Pyrazole Compounds, Formulations Thereof, and a Method for Using the Compounds and/or Formulations
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Patent:
48,898 →
Application:
16/291,992 →
Prodrugs of NRF2 Activating Compounds and Uses Thereof
Prodrugs of Nrf2 Activating Compounds and Uses Thereof
Modulators of angiogenesis and tumorigenesis
Quinoline Compounds and Their Uses
Ubiquitin Ligase Inhibitors
Shrna Library
Multidimensional Biodata Integration and Relationship Inference
Methods of Identifying Compounds That Modulate Il-4 Receptor-Mediated Ige Synthesis Utilizing a C-Myc Protein
Methods of Identifying Compounds That Modulate Il-4 Receptor Mediated Ige Synthesis Utilizing a CLLD8 Protein
Bi-Directionally Cloned Random Cdna Expression Vector Libraries, Compositions and Methods of Use
Methods of Identifying Compounds That Modulate Il-4 Receptor-Mediated Ige Synthesis Utilizing a B-Cell Associated Protein
Methods of Identifying Compounds That Modulate Il-4 Receptor-Mediated Ige Synthesis Utilizing an Adenosine Kinase
Modulators of Leukocyte Activation, Compositions and Methods of Use
NP95: Methods of Assaying for Cell Cycle Modulators
Modulators of Leukocyte Activation, Compositions and Methods of Use
LETM1: Modulators of Cellular Proliferation
Organic Semiconductor Composition, Organic Thin Film Comprising Same, and Use Thereof
Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Related Assignments
(22)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Sep 4, 2019
From: ARGADE, ANKUSH; SRAN, ARVINDER; CARROLL, DAVID; CLOUGH, JEFFREY
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 050263/0621 →
Assignment of Assignor's Interest
Apr 7, 2020
From: SINGH, RAJINDER; BHAMIDIPATI, SOMASEKHAR; MASUDA, ESTEBAN; SUN, THOMAS
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 052326/0001 →
Assignment of Assignor's Interest
Jun 16, 2020
From: CHEN, YAN; YEN, ROSE; YU, JIAXIN; TAYLOR, VANESSA
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 052953/0069 →
Assignment of Assignor's Interest
Jul 10, 2020
From: BHATT, RAMESH R.; KINSELLA, TODD; LI, WEI
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 053175/0268 →
Assignment of Assignor's Interest
Feb 9, 2021
From: SCHULZ, HAKAN; SMITH, REED WARREN, JR
To: ASTRAZENECA AB
Reel/Frame 055197/0468 →
Assignment of Assignor's Interest
Mar 10, 2021
From: TSO, KIN; LI, HUI; CHEN, YAN; YEN, ROSE
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 055553/0265 →
Assignment of Assignor's Interest
Mar 10, 2021
From: LI, HUI; HECKRODT, THILO; CHEN, YAN; KELLEY, RYAN
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 055553/0234 →
Assignment of Assignor's Interest
Jun 3, 2021
From: SINGH, RAJINDER; ARGADE, ANKUSH; PAYAN, DONALD G.; MOLINEAUX, SUSAN
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 056431/0850 →
Assignment of Assignor's Interest
Jun 3, 2021
From: GELMAN, MARINA; DING, PINGYU; KINSELLA, TODD; SINGH, RAJINDER
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 056431/0923 →
Assignment of Assignor's Interest
Jun 29, 2021
From: YEN, ROSE; CHEN, YAN; TAYLOR, VANESSA
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 056700/0225 →
Assignment of Assignor's Interest
Aug 4, 2021
From: KINSELLA, TODD M.; BHATT, RAMESH; BALTGALVIS, KRISTEN
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 057083/0835 →
Assignment of Assignor's Interest
Oct 6, 2021
From: LI, HUI; HECKRODT, THILO J.; CHEN, YAN; MCMURTRIE, DARREN JOHN
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 057714/0215 →
Assignment of Assignor's Interest
Nov 9, 2021
From: SINGH, RAJINDER; SHAW, SIMON; ISSAKANI, SARKIZ; LIN, NAN
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 058057/0614 →
Assignment of Assignor's Interest
Nov 18, 2021
From: YU, JIAXIN; BHAMIDIPATI, SOMASEKHAR; HOLLAND, SACHA; SINGH, RAJINDER
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 058739/0253 →
Assignment of Assignor's Interest
Jan 13, 2022
From: HITOSHI, YASUMICHI; HOLLAND, SACHA; PAYAN, DONALD G.
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 058641/0718 →
Assignment of Assignor's Interest
Feb 11, 2022
From: SINGH, RAJINDER; ARGADE, ANKUSH; LI, HUI; BHAMIDIPATI, SOMASEKHAR
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 058990/0471 →
Assignment of Assignor's Interest
Mar 16, 2022
From: YEN, ROSE; CHEN, YAN; TAYLOR, VANESSA; SINGH, RAJINDER
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 059287/0056 →
Assignment of Assignor's Interest
Mar 31, 2022
From: MASUDA, ESTEBAN; SINGH, RAJINDER; TAYLOR, VANESSA; PAYAN, DONALD G.
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 059456/0172 →
Assignment of Assignor's Interest
Apr 1, 2022
From: LI, HUI; THOTA, SAMBAIAH; CARROLL, DAVID; ARGADE, ANKUSH
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 059568/0738 →
Assignment of Assignor's Interest
May 24, 2022
From: KELLEY, RYAN; LI, HUI; HECKRODT, THILO; CHEN, YAN
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 059996/0102 →
Assignment of Assignor's Interest
Aug 5, 2022
From: ASTRAZENECA AB
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 060737/0993 →
Security Interest
May 8, 2026
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 075576/0880 →